Kyung-Don Kang

发表

Targeting Oncometabolism to Maximize Immunotherapy in Malignant Brain Tumors

E. Thompson, V. Darley-Usmar, D. Segar, 2022, Oncogene.

The Serum Very-Low-Density Lipoprotein Serves as a Restriction Factor against Hepatitis C Virus Infection

J. Novak, M. Renfrow, Jia Liu, 2015, Journal of Virology.

Clinical advances in oncolytic virotherapy for pediatric brain tumors.

M. R. Chambers, J. Johnston, J. Markert, 2022, Pharmacology & therapeutics.

Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.

J. Johnston, J. Markert, J. Fiveash, 2021, The New England journal of medicine.

Immunotherapy approaches for the treatment of diffuse midline gliomas

Mariella G. Filbin, W. Essayed, J. Bernstock, 2022, Oncoimmunology.

Intraventricular immunovirotherapy; a translational step forward

J. Bernstock, G. Friedman, Kyung-Don Kang, 2023, Oncotarget.

Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.

L. J. Lee, Zhihong Chen, Xinghua Lu, 2018, Cancer research.

Oncolytic Herpes Simplex Virus Immunotherapy for Brain Tumors: Current Pitfalls and Emerging Strategies to Overcome Therapeutic Resistance

J. Markert, E. Beierle, J. Bernstock, 2019, Oncogene.

Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission

Wensheng Wei, Huahao Fan, Junfen Fan, 2017, Journal of Virology.

Safety and efficacy of intraventricular immunovirotherapy with oncolytic HSV-1 for CNS cancers.

J. Markert, R. Wechsler-Reya, S. Bae, 2022, Clinical Cancer Research.